April 02, 2025 10:42 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
In a major boost for tourism, Shimla to get Asia's longest ropeway spanning 13.79 kilometers | Karnataka govt hikes sales tax on diesel, price goes up by Rs. 2 | 'Heard India will be dropping its tariffs substantially': Donald Trump ahead of announcing reciprocal tariff | Opposition MPs decide to vote against Waqf Amendment Bill in Parliament tomorrow | Chilean President Boric visits India, discusses ways to expand bilateral ties with Modi | Himanta Biswa Sarma slams Muhammad Yunus' Northeast remarks, Tripura leader suggests Bangladesh's split | Modi govt determined to uproot Naxalism by March 31, 2026: Amit Shah | Time for reciprocity: White House refers to India's 100 percent tariff imposed on US agri products ahead of April 2 deadline | Fresh encounter breaks out in J&K's Kathua, security forces trap 3 terrorists | Pakistani advocacy group nominates Imran Khan for Nobel Peace Prize
COVID-19 Vaccine
AdarPoonawala Twitter page

COVID-19 vaccine is safe, says Serum Institute of India on side effect claims  

| @indiablooms | Dec 01, 2020, at 10:13 pm

Pune-based  Serum Institute of India's (SII) said its 'COVISHIELD' vaccine is safe and immunogenic after a volunteer claimed that he suffered neurological and psychological side effects after taking a shot of the vaccine.

Rejecting all allegations, the institute said: "The incident with the Chennai volunteer though highly unfortunate was in no way induced by the vaccine and Serum Institute of India is sympathetic with the volunteer's medical condition. "

"However, we would like to clarify that all the requisite regulatory and ethical processes and guidelines were followed diligently and strictly," the institute said.

"The concerned authorities were informed and the Principal Investigator, DSMB and the Ethics Committee independently cleared and reckoned it as a non-related issue to the vaccine trial. Post which we submitted all the reports and data related to the incident to the DCGI. It is only after we cleared all the required processes that we continued with the trials," read the statement.

The Pune based institute said the vaccine will not be released for mass use unless it is proven immunogenic, and safe.  

"Taking into consideration the complexities and existing misnomers about vaccination and immunisation; the legal notice was sent therefore to safeguard the reputation of the company which is being unfairly maligned," it said.

The institute is conducting clinical trials of the  AstraZeneca-Oxford's Covid-19 vaccine in India.

The phase-3 clinical trial of the vaccine is currently being made across India.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.